Payment overview · 2025
General Payments
$1,127.80
58 reported records · 16 companies
Healthcare provider profile · identity verified
Keith Beck, MD
Allopathic & Osteopathic Physicians|General Practice · SAN ANTONIO, TX · NPI 1740280999
Verified facts
What the public records show
CMS Open Payments records show Keith Beck, MD received $1,127.80 in general payments during 2025 across 58 reported records.
ABBVIE INC. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $359.09 | 31.8% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $203.18 | 18.0% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.36 | 12.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $75.00 | 6.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.10 | 5.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.96 | 4.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.72 | 3.6% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $40.13 | 3.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.11 | 2.7% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.08 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.70 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.78 | 1.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.82 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.64 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.78 | 1.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.35 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,127.80 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $185.28 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $156.58 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $129.04 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $129.04 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $120.52 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $75.00 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $74.14 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.96 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
50 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 85 |
| Lisinopril | Lisinopril | 257 | 90 |
| Losartan Potassium | Losartan Potassium | 186 | 62 |
| Alprazolam | Alprazolam | 175 | 29 |
| Metformin Hcl | Metformin Hcl | 174 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 170 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 22 |
| Omeprazole | Omeprazole | 137 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 46 |
| Gabapentin | Gabapentin | 121 | 42 |
| Simvastatin | Simvastatin | 110 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 33 |
| Trazodone Hcl | Trazodone Hcl | 99 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 30 |
| Montelukast Sodium | Montelukast Sodium | 89 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 27 |
| Jardiance | Empagliflozin | 78 | 23 |
| Furosemide | Furosemide | 75 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 23 |
| Alendronate Sodium | Alendronate Sodium | 57 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 19 |
| Ozempic | Semaglutide | 54 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Allopurinol | Allopurinol | 51 | 17 |
| Prolia | Denosumab | 50 | 33 |
| Carvedilol | Carvedilol | 49 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 13 |
| Meloxicam | Meloxicam | 47 | 23 |
| Tramadol Hcl | Tramadol Hcl | 47 | 18 |
| Finasteride | Finasteride | 46 | 16 |
| Baclofen | Baclofen | 45 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 15 |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Potassium Chloride | Potassium Chloride | 40 | 18 |
| Sertraline Hcl | Sertraline Hcl | 39 | 15 |
| Eliquis | Apixaban | 37 | 11 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 11 |
| Prednisone | Prednisone | 34 | 24 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 15 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 13 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Euthyrox | Levothyroxine Sodium | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Tretinoin | Tretinoin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,127.80 · 58 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, CONTRAVE, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, JATENZO, Kerendia, NURTEC ODT, OFEV, OTEZLA, Omnipod, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VENASEAL, VRAYLAR, Wegovy, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error